Zambon Expands in Europe Acquiring Nigaard

Milan (ots/PRNewswire) -

The deal will speed up the commercialization of Xadago(R) for the
treatment of

Parkinson's Disease

Nigaard is a pharmaceutical company well established in Denmark,
Norway, Sweden,

Iceland and Finland

Zambon S.p.A., an international pharmaceutical company strongly
committed to the Central Nervous System (CNS) therapeutic area and
the Respiratory area with a focus on Rare Diseases, announced today
the acquisition of Nigaard, a full service specialised company
headquartered in Oslo, Norway.

(Logo: http://photos.prnewswire.com/prnh/20150515/744259 )

Established in 2002, Nigaard is a licensed pharmaceutical company
focused on Respiratory and Allergy, including pharmaceuticals and
medical devices, well developed in all the countries of Northern
Europe: Denmark, Norway, Sweden, Iceland and Finland. It is currently
Promixin(R) distributor for Sweden and Norway, as well as owner of
several distribution and licensing agreements.

With the acquisition of Nigaard, that follows the Profile Pharma
deal in UK in 2013 and the re-establishment of a branch in Germany in
2014, Zambon is now covering all the Western Europe markets.

Maurizio Castorina, CEO of Zambon SpA stated: "The Nordic
countries are very interesting for the investments' plan of Zambon
both because of the high standards on Healthcare System and the
dimension of the market, with a population of 25 million. Nigaard is
a well-known organization with an important capillarity in Northern
Europe and its acquisition is an important step forward to speed up
the commercialization of Xadago(R) , for the treatment of Parkinson's
Disease, and the development of Promixin(R), our inhaled antibiotic
for bronchial infections in Cystic Fibrosis. The expansion of Zambon
will also increase our professional competences in the specialties
business as key success factor."

Zambon Regional General Manager for Northern & Central Europe,
Roberto Antonini, also commented: "We have the great opportunity to
approach the Scandinavian region with a full control of regulatory,
distribution and promotional affairs. Nigaard people have the right
skills and competences and this acquisition will also boost our
internationalization process after UK in 2013 and Germany last year."

About Zambon

Zambon is a leading Italian pharmaceutical and fine-chemical
multinational business with a strong reputation for high quality
products and services. The Group is strongly working on the treatment
of the chronic respiratory diseases as asthma and COPD and on the CNS
therapeutic area with Xadago(R) (safinamide), licensed by Newron, for
the Parkinson treatment. Zambon is also well-established in 3
therapeutic areas: Respiratory, with a focus on Rare Disease and in
particular on Cystic Fibrosis, Pain and Women's care. Zambon SpA
produces high quality products thanks to the management of the whole
production chain which involves Zach (Zambon chemical), a privileged
partner for API, custom synthesis and generic products. Headquartered
in Milan and established in 1906 in Vicenza, Zambon has branches in
15 countries and more than 2,600 employees with manufacturing units
in Italy, Switzerland, France, China and Brazil. Zambon products are
commercialized in 73 countries.

For details on Zambon please see: http://www.zambongroup.com

About Nigaard

Nigaard was created in 2002 in Oslo by Kjetil Herland. After some
25 years working mainly in large pharma companies in the Nordic area,
he decided to start a new full-service pan Nordic distribution
company focusing on Respiratory diseases and allergy. Since the
beginning, the company has formed a small-specialized team, built
good access to key opinion leaders and a majority of the key
specialized doctors, established a growing reputation as a good
Nordic partner and secured the distribution rights for products in
the Nordic area. Nigaard provides full service, pan-Nordic market
access for large international Pharmaceutical companies.

For further information
Media
Zambon
CCO
Luca Primavera
Phone: +39-02-66524491
Mobile: +39-335-7247417
Email: luca.primavera@zambongroup.com

Germana Mancino
Email: gmancino@webershandwick.com
Ph: +39-3492625439
Weber Shandwick

Photo:
http://photos.prnewswire.com/prnh/20150515/744259

ots Originaltext: Zambon S.p.A.
Im Internet recherchierbar: http://www.presseportal.de

Contact:
GIOVANNA GIACALONE - Mob: +39-349-7738681
Ggiacalone@webershandwick.com